DFC Dialysis Facility Compare g/dl UPR65% UPR BUN BUN/ BUN NEJM, March10,2005 Anemia of C

Similar documents

125 2 P 1st washout 2 PB P mg/dL nd washout 2 P 5.5mg/dL< mg/dL <2.5mg/dL P P 2 D D 3 Ca 10

_”÷’X

橡DI月報200.PDF

2

untitled

387 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )

(1) ) ) (2) (3) (4) (5) (1) (2) b (3)..

‡È‡¢‡Ó‡éNo.46



BUN, CRP K mg/ cm, 49.6 kg, BMI /72 mmhg, 92/ Hb 6.7 g/dl PT-INR CT 1 MRI 2a, b T1 T2 T1 MRI

I

溶血性尿毒症症候群 ver 最終.pptx

/12/28 UP 3+, TP 4.2g/dl, Alb 1.9g/dl PSL 50mg/day 1/17 PSL 45mg/day PSL 2006/4/4 PSL 30mg/day mpsl mpsl1000mg 3 2 5/ :90 / :114/64 mmhg

mg 8 mg X Cr 9.84 mg/ dl K 1.5 meq/l CK 24,570 U/L Mb 79,530 ng/ml Mb 230,000 ng/ ml AKI 2 IHD IHD 4 IHD


untitled

第5回東京都廃棄物審議会

西食堂

フィジカルコンディショニング

PowerPoint プレゼンテーション

支援リスト3/30.xls

untitled

かんたん操作ガイド[arrows M02]

かんたん操作ガイド[arrows RM02]



かんたん操作ガイド[arrows M03]

Sample2 g/dl Target1 : 6.01 g/dl TP Target2 : 8.39 g/dl

Microsoft Word - 表紙資料2-4

食事編_表1_4_0508

11太陽電池作品集表1

高脂血症の検査

n

社会システム研究25_ 徐林.indd

平成25年度調理師試験問題

.T.C.Y._.E..

無印良品のスキンケア

....

1総説_諸疾患における亜鉛測定の意義.indd


20-121

JC44104

表 K/DOQI ガイドラインに示された骨ミネラル代謝マーカーの管理目標値 CKD P mg/dl Ca mg/dl 7.CKD に伴う骨ミネラル代謝異常 ipth pg/ml KDOQI 表 b

untitled


Q A ワークショップ 肥 満 症 Q&A パート1 概 念 成 因 合 併 症 Q1: 長 谷 川 和 田 LDL HDL EPA LDL HDL EPA HDL CRP () 和 田 中 村 相 澤 Q2:HbA1C 長 谷 川 佐 藤 m

自大病院だより-23号-cs5.indd

2.7.6 MJR a MRI CT b 2 Beecham r-afs mg/ mg/ Gn-RH 742

Nutrition and hemodialysis status of long-surviving hemodialysis patients Hiroshi Watanabe*1, Yoshiko Okada*2, Masahiro Mori*1, Takashi*2, Hidehiro Ta

Taro9-医薬品目次2012-1.PDF

Efficacy of Colestimide as a phosphate binder in patients on chronic hemodialysis Toshiyuki Date, Yoshiteru Kawashita, Nobuyoshi Satake Jin-ai-kai Dat


2010 年 6 月 25 表 身体所見 134 cm 31 kg /60 mmhg 83/ ,

BMI BMI


/ B B ( ) ( -298) VL VH( ) Very Low( ) Very High( ) ( 10 2 %) (g/l) ( 10 2 %) 0.75 ( 10 2 %) 0.15 ( 10 2 %)

12

sick contact1l

CD口頭目次.indd

無水エタノールによる硬化療法および鼻粘膜癒着処置を施行したオスラー病による難治性鼻出血の1例

A B 1.A B A B 2.A B A B 3.A

16 9 Paula TFC BMI PSL hydroxysteroid dehydrogenase (11 -HSD) modulator ( prereceptor mod

051

0.02ml IgE RAST MAST CAP 2

近畿中国四国農業研究センター研究報告 第7号


_02三浦.indd

1 Blood chemistry Peripheral blood Viral marker TP 5.4 g dl WBC ml Syphilis TPAb Alb 2.7 g dl RBC ml HBsAg T. bil 2.3 mg dl Hb 11 g dl

九州支部卒後研修会症例

[] 1

日本呼吸器学会雑誌第44巻第10号

EL-G37

C-reactive protein (CRP) and risk factors of atherosclerosis in chronic hemodialysis patients Kenji Yuasa, Hiroaki Sugiyama, Tetsuo Kouzi, Kazuhiro Ma


橡アロマセラピー症状別処方例.PDF

河口洋行133‐154/133‐154

表1

は 95% 信頼区間をみると 少なくとも悪い結果の可能性はかなり低い Using data from all 6 relevant trials, the pooled odds ratio for cramping after L-carnitine supplementation was 0.3

本文/一般演題_吉田

fringe benefit FEHB Federal Employees Health Benefits States Employee Health Benefits Medicare 1965 TitleX VIII of the Social Security Act1966

v

ph

No ( FAX ) (

08症例報告4山内.indd

1) a) b) CRP c) d) e) a,b b,c c,d d,e a,e b,d 2) CKD a) ACE ARB b) 2mg/dL ACE ARB c) 2mg/dL d) e) ACE ARB a,b b,c c,d d,e a,e b,d 3) a) 130/85mmHg b)

Ł\”ƒ1-4

VOL.39 S-3

37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate

日本呼吸器学会雑誌第44巻第1号


untitled

March

- 9 91, (2006)

Medical Journal of Aizawa Hospital

L- 19 L L- L-


油汚染鳥救護のガイドライン


Transcription:

HemodialysisReview Article: Medical ProgressNEJM, Nov.4, 2010 H23.1 80 20 1 Dialyser NEJM 1 6.6 15.6 21.7 1 21.7 AV fistula 3 1 4 1 1980 Kt/V urea Vml t 1.4 8 12 DFC: Dialysis Facility Compare

DFC http://www.cms.gov/dialysisfacilitycompare/ Dialysis Facility Compare 3 10.0 12.0g/dl UPR65% UPR BUN BUN/ BUN 11 12 NEJM, March10,2005 Anemia of Chronic Disease TFC:080703010 10 Hb 8 10 11 odds Ht 33 36 Hb Hb 11 12 erythropoietin 25 Brookline Dialysis Massachusetts General Hospital 10 3 Massachusetts General Hospital 17 Brookline Dialysis 3 12 16 Massachusetts General Hospital 0 % Brookline Dialysis 4 UPR65

96 Massachusetts General Hospital 100% Brookline Dialysis 99 2006 2009 441 3995 562 Massachusetts General Hospital Brookline Dialysis NEJM 1972 75 2008 MIPPA: Medicare improvements for Patients and Providers Act bundled payment 2011 erythropoietin cherry-picking : NEJM 16

NEJM 1. 2. 4 3 3. 200ml 400ml/ 4. 2 5. 10ml/kg/h 6. Kt/V urea 1.4 7. 5 8. Hb 10 12 9. 10. Kt/V urea 11. 12. 13. 3 14. http://www.cms.gov/dialysisfacilitycompare/. 15. 1 6.6 15.6 21.7 16. Hemodialysis Review Article: Medical Progress NEJM, Nov.4, 2010 H23.1 Jonathan Himmelfarb, M.D. T.Alp Ikizler, M.D. Vanderbilt 50 Belding Scribner blood-access Scribner AV fistula 100

dialysatebicarbonate compartmentalized 2microglobulin p-cresol ultrafiltration 10ml/kg/h sorbent Dialyzer: hollow-fiber dialyzer High-flux membrane low-flux membrane 4 3 QOL 200ml 400ml/ blood-access dialysate 2

Ultrafiltration 10ml/kg/h Nasodium 130 145mmol/L Na Kpotassium 2 3mmol/L K K K 30 Ca 1.25 1.75mmol/L Ca Ca Mg 0.5mmol/LMg Mg flux Alkaline buffers 30 40mmol/L. Chloride alkaline buffer Glucose 100 200mg/dl D

single-pool Kt/Vurea>1.4 5 ultrapure 10 12g/dl AV fistula() Ca 8.4 9.5mg/dlP 3.5 5.5mg/dl Intact PTH 2 D phosphate binder PTH 4.0g /dl PKNa LDL 100mg/dl Quantifying the dose and adequacy of dialysis Kt/V urea K 1 mlt V urea Kt/Vurea Vml t 500 30000 high-flux

2microglobulin high-flux 1980 1 8 12 40 3 3 CaP QOL 1972 ESRD: End-Stage Renal Disease 1972

75 2008 MIPPA: Medicare improvements for Patients and Providers Act (ESRD) bundled payment 2011 cherry-picking : 2003 CMSCenters for Medicare and Medicaid Services arteriovenous fistulas Fistula First fistula CMS DFC (Dialysis Facility Compare) http://www.cms.gov/dialysisfacilitycompare/. Dialysis Facility Compare 20 2 20 13 2 / 1 / 1996 2002 1 6.6 15.6 21.7

AV fistule() tunneled catheter 1970 NCDSthe National Cooperative Dialysis Study single-pool Kt/V urea V ml t 1.2 1990 higher permeability characteristics Kt/V urea 1.4 Homocysteine erythropoietin p-cresol sulfateindoxyl sulfate phosphate

NEJM 1. 2. 4 3 3. 200ml 400ml/ 4. 2 5. 10ml/kg/h 6. Kt/V urea 1.4 7. 5 8. Hb 10 12 9. 10. Kt/V urea 11. 12. 13. 3 14. http://www.cms.gov/dialysisfacilitycompare/. 15. 1 6.6 15.6 21.7 16.